Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TPX 100 (Primary)
  • Indications Meniscus disorders; Osteoarthritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors OrthoTrophix

Most Recent Events

  • 08 Oct 2021 Primary endpoint has been met. (Change in cartilage thickness in the patello-femoral compartment as measured on standardized MRI from baseline to 12 months), according to an OrthoTrophix media release.
  • 08 Oct 2021 Results presented in an OrthoTrophix media release.
  • 17 Sep 2021 According to an OrthoTrophix media release, results from the study were published online by Arthritis Research & Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top